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A multi-center, double-blind, 90-day study compared an ipratropium 
bromide metered-dose inhaler (40 pg four times a day) with a meta- 
proterenol metered-dose inhaler (1,500 pg four times a day) in 164 
patients with asthma; of the 144 patients who completed the study, 
71 received ipratropium and 73 received metaproterenol. Our re- 
sults suggest that both drugs were equally effective bronchodila- 
tors. Although the shape of the pulmonary function response 
curves suggested that ipratropium has different bronchodilator ki- 
netics than metaproterenol (in that it has a slower onset of action 
and a more prolonged duration), comparison of the areas under the 
curves for the two drugs showed that there was no statistical differ- 
ence between ipratropium or metaproterenol. The only significant 
side effects noted with ipratropium were cough and exacerbation of 
symptoms; no anticholinergic side effects were noted. 
Although anticholinergic drugs have not previously been approved for 
use in the treatment of asthma in the United States, many physicians use 
aerosolized atropine, delivered by a compressor-nebulizer, for the treat- 
ment of bronchospasm [l]. lpratropium bromide, a quaternary derivative 
of atropine, was developed to provide bronchodilation without anticholin- 
ergic side effects, such as dry mouth and tachycardia. The current study 
was conducted to evaluate the efficacy and safety of ipratropium bro- 
mide, delivered by a metered-dose inhaler, in the treatment of patients 
with asthma over a go-day period. 
PATIENTS AND METHODS 
This double-blind, randomized, parallel, multi-center trial was conducted at 
five sites in the United States: Colorado Springs, Colorado; Madison, Wiscon- 
sin; Denver, Colorado; Portland, Oregon; and Ann Arbor, Michigan. The study 
objective was to compare the safety and efficacy of ipratropium bromide with 
those of a standard beta-adrenergic bronchodilator, metaproterenol sulfate. 
Both drugs were delivered by metered-dose inhalers. All patients who entered 
the study met the American Thoracic Society criteria for bronchial asthma. 
Patients ranged in age from 13 to 50 years, with an average age of 31 .O 
years. There were 82 male and 82 female patients enrolled. Each patient had 
a forced expiratoty volume in one second (FEV,) of less than 75 percent of 
predicted normal, and a ratio of FEV, to forced vital capacity of less than 70 
percent. In addition, reversibility of airways obstruction was required, as evi- 
denced by a 15 percent or greater improvement of FEV, within 30 minutes 
after inhalation of two puffs (0.15 mg) of isoproterenol from a standard me- 
tered-dose inhaler. Patients with any significant medical diseases, prostate 
disease, bladder neck obstruction, narrow-angle glaucoma, or a clinical diag- 
nosis of chronic bronchitis were excluded from the study. Also excluded were 
patients who were hypersensitive to sympathomimetic or anticholinergic 
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agents; patients who were or expected to become pregnant; 
patients who smoked regularly during the previous year or 
who had a smoking history of more than 10 pack-years; and 
patients with chronic sputum production. Before the start of 
the study, electrocardiograms, complete blood cell counts, 
biochemical surveys, and urinalyses were obtained for all 
patients; patients with clinically significant abnormalities on 
these tests were excluded. Prior to entry in the study, all pa- 
tients gave written informed consent, according to the guide- 
lines of each investigator’s local committee for the protection 
of human rights. 
After the screening visit, patients entered a two-week 
washout period during which all oral and inhaled beta-adren- 
ergic bronchodilators and all anticholinergic drugs were ex- 
cluded. They then entered the go-day period of the study in 
which they were randomly assigned to one of two treatment 
groups: ipratropium, two puffs (40 pg) four times a day, or 
metaproterenol, two puffs (1,500 pg) four times a day. Pa- 
tients were instructed as to the proper use of a metered-dose 
inhaler. 
Concomitant medications that were allowed during the 90- 
day period were oral theophylline products, inhaled steroids, 
inhaled cromolyn sodium, and antibiotics; doses of these 
agents (except for the antibiotics) had to be stable throughout 
the study. Oral cotticosteroids were only allowed if the dos- 
age was stable and was equal to or less than 20 mg of pred- 
nisone (or its equivalent) every other day. Any patient who 
required an increased dose of steroids during the study was 
allowed to continue in the study only if the increased dose did 
not last more than five days and if there were no more than 
two of these increased dosage periods. No inhaled broncho- 
dilators, other than the study drugs, were allowed. For the 
treatment of an acute asthmatic episode during the study pe- 
riod, parenteral epinephrine, parenteral terbutaline, or intra- 
venous aminophylline were the only drugs permitted. 
The first day of the go-day treatment period began with a 
clinic visit at which pulmonary function tests monitored over 
six hours were given. In preparation for this and the other 
pulmonary function test days, patients discontinued all medi- 
cation the evening before the visit. Spirometry (FEV,, forced 
vital capacity, forced expiratory flow between 25 and 75 per- 
cent of forced vital capacity, and peak expiratoty flow rate) 
was performed at baseline, at five, 15, and 30 minutes, and at 
one, two, three, four, five, and six hours after drug administra- 
tion. Each patient was given the blinded metered-dose in- 
haler, which was then used on a daily basis at home for the 
next 90 days. Each patient was instructed and observed dur- 
ing the administration of the medication for proper inhalation 
technique. Pulse and blood pressure were recorded at the 
same time points as the pulmonary function tests were done. 
No caffeinated beverages were allowed at any time during 
this six-hour pulmonary function test day. Identical proce- 
dures for pulmonary function testing were followed on days 
45 and 90. 
Bronchodilator efficacy was evaluated on the basis of the 
FEV, response to drug treatment. The primary measure of 
FEV, efficacy that was used for the statistical analysis was 
the area under the FEV, curve (calculated using the trapezoi- 
dal rule). Treatment comparisons were made using an analy- 
sis of covariance. The statistical model also included terms 
for treatment and clinics. Median durations of action among 
patients who showed a response were compared using the 
median test. 
RESULTS 
Originally, 164 patients were entered into the study, but 
only 144 completed the full go-day period and were avail- 
able for the statistical analysis of pulmonary function. Nine 
patients in the ipratropium group dropped out: three who 
were lost to follow-up and six because of lack of efficacy. 
From the metaproterenol group, seven patients dropped 
out: three because of side effects; two who were lost to 
follow-up; one because of lack of efficacy; and one for 
protocol violation. Seventy-one of the 144 patients re- 
ceived ipratropium, and 73 received metaproterenol. 
All 164 patients were included in the summary of patient 
characteristics. The two treatment groups were compared 
as to age, sex, height, weight, asthma history, and other 
parameters. There were no significant differences be- 
tween the treatment groups; they were comparable in 
median age, median age of asthma onset, and median 
height and weight. Table I summarizes important parame- 
ters for the two groups. Baseline values for FEV, on day 1 
prior to drug administration were not significantly different 
(ipratropium 2.44 liters, metaproterenol 2.32 liters). 
The prior use of asthma medications by each of the two 
treatment groups was recorded. More patients in the 
ipratropium group (43) had a past history of steroid use 
than in the metaproterenol group (27), but this was not 
statistically significant. During the study, steroid use was 
comparable between the two groups. In addition, both 
groups used equivalent amounts of medications. Nearly 
all of the patients required theophylline, and approxi- 
mately 25 percent of the patients in each group received 
inhaled steroids. 
The mean FEV, (adjusted for baseline differences) val- 
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Figure 1. Changes in FEV, for all Pa- 
tients on days 1 (top), 45 0nkkfW and 
90 (bottom). 
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ues at each time after drug administration on study days 
1, 45, and 90 are shown in. Figure 1. On day 1, the area 
under the curve for metaproterenol was slightly larger 
than for ipratropium, but this was not statistically signifi- 
cant (p = 0.15). On day 45, the areas under both curves 
were almost identical, and on day 90, the area for 
ipratropium was larger than that for metaproterenol. The 
differences in areas under the curves were not statistically 
significant. 
When the pulmonary function responses were exam- 
ined closely, it became apparent that a number of patients 
in each treatment group had no bronchodilator response 
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TABLE II Bronchodilator Efficacy in Responders 
lpratropium Metaprolerenol 
Day Day Day Day Day Day 
FEY, (liters) 1 45 90 1 45 90 
Onset of 15 percent or greater 
increase in a majority of 
patients (minutes) 515 515 515 55 55 55 
Median duration of 15 percent 
or greater increase (hours) 5.5 3.0 5.0’ 4.0 3.0 2.0 
Median time to peak effect 
(hours) 2.0 2.0 1.5 1.0 0.5 0.25 
*Significant difference in favor of ipratropium. 
TABLE III Number of Patients with Adverse 
Experiences Following Treatment with 
lpratropium or Metaproterenol* 
lpratropium Metaproterenol 
(81 patients (83 patients 
treated) treated) 
Number Percent Number Percent 
Tachycardia 
Palpitations 















Exacerbation of symptoms 
Cough 
0 0 I 1.2 
0 0 3 3.6 
3 3.7 3 3.6 
5 6.2 14 16.9 
4 4.9 2 2.4 
1 1.2 1 1.2 
0 0 1 1.2 
0 0 1 1.2 
1 1.2 1 1.2 
0 0 1 1.2 
1 1.2 0 0 
0 0 2 2.4 
6 7.4 1 1.2 
8 9.9 2 2.4 
*For original cohort of 164 patients. 
and that this obscured the interpretation of the response 
characteristics such as onset, duration, and time to peak 
effect. Patients were therefore classified as responders or 
non-responders based on whether or not they achieved at 
least a 15 percent increase over baseline FEVr values 
within two hours following the test dose on day 1. Forty of 
78 (51 percent) of the patients receiving ipratropium and 
56 of 77 (73 percent) of the patients receiving metaproter- 
enol were defined as responders by this definition. In re- 
sponders, the onset of bronchodilation was slower and the 
time to peak effect and duration of action longer with 
ipratropium than with metaproterenol (Table II). A statisti- 
cal search technique [2] did not reveal any physical or 
clinical characteristics that might be predictive of re- 
sponse to ipratropium. 
Global evaluations of asthma symptoms performed by 
physicians at two-week intervals showed that both treat- 
ment groups had almost’identical scores. No differences 
whatsoever were noted in the severity of day-to-day 
asthma in either treatment group. 
Pulse rates and blood pressure determinations were 
recorded during the pulmonary function testing days. On 
each test day, mean pulse decreased about two to five 
beats per minute with both ipratropium and metaprotere- 
nol. These decreases reached statistical significance with 
respect to baseline, but not between the drugs. After treat- 
ment with both drugs, the mean systolic and diastolic 
blood pressure readings declined 0 to 4 mm Hg from the 
baseline measurements on each of the pulmonary func- 
tion test days. None of the changes in either pulse rate or 
blood pressure was clinically significant. The laboratory 
analyses before and after the go-day treatment period, 
including complete blood cell counts, biochemical sur- 
veys, electrocardiograms, and urinalyses, did not reveal 
any abnormalities that were deemed to have any clinical 
significance by the investigators. There were no statisti- 
cally significant differences in the mean laboratory vaiues 
compared with baseline values in either treatment group 
during the 90 days of study. 
Table Ill shows adverse experiences associated with 
the drugs. The most common adverse experiences noted 
in the ipratropium group were cough and exacerbations of 
symptoms. Side effects attributed to metaproterenol in a 
total of three patients were shakiness (two patients), 
headache and dizziness (one patient), and nervousness, 
face and body rash, and mouth irritation (one patient). 
Tachycardia, palpitations, and tremor were not observed 
with ipratropium, but occurred in 4.8 percent of the pa- 
tients who received metaproterenol. 
COMMENTS 
Anticholinergic drugs have not previously been approved 
in the United States for the treatment of asthma, and their 
use has been restricted to the aerosol solution form of 
atropine, delivered by a compressor nebulizer system [3]. 
In addition, aerosolized atropine is absorbed and may 
produce systemic anticholinergic side effects, which fur- 
ther limits its use. Therefore, ipratropium bromide, a qua- 
ternary ammonium anticholinergic that is notably free of 
atropine-like side effects, has generated considerable in- 
terest for use in asthma therapy. 
Since ipratropium has not previously been used in the 
United States, it is difficult to identify completely its place 
in the armamentarium of drugs that are available for 
asthma. Previous studies have shown that ipratropium is 
an effective bronchodilator, but one that has notable dif- 
ferences from the beta-adrenergic agonists [4,5]. Al- 
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lergen-induced bronchospasm is only partially prevented 
by pretreatment with ipratropium [6]. In that model, 
ipratropium is not as effective as a beta agonist. The use 
of ipratropium in coinblnation with theophylline, a beta 
agonist, and & ortil steroid has been evaluated [7]. 
lpratropium gives an additive bronchodilator effect when 
used with these drugs. Since ipratropium has different 
pharmacolbgic effects than those of the beta-adrenergic 
agonists, its role in the treatment of patients with asthma 
is not established, althoudh it is likely to be used as a 
second-line, or adjunctive, form of therapy. 
Other studies have suggested that there may be spe- 
cific indications tor ipratropium in certain asthmatic pa- 
tients, such as those whose asthma is brought on by psy- 
chogenic factors [8,9], cigarette smoke [lo], or beta- 
blocking drugs [ll]. Thus, there may be certain specific 
triggering factors that would produce an indication for the 
use of ipratropium in a given patient with asthma. 
Although our study indicates that there is a subset of 
patients with asthma who show a better response to 
ipratropium than to beta-adrenergic agonists, we were 
unable to characterize these patients; therefore, one can- 
not predict the effectiveness of this treatment without a 
therapeutic trial. 
One major strength of ipratropium is its safety. The cur- 
rent study found no significant adverse reactions caused 
by use of ipratropium for 90 days. Similar results were 
found in other studies [12,13]. This safety profile makes 
ipratropium quite appealing, especially since it may be 
used with other anti-asthmatic drugs, such as beta-adren- 
ergic agonists or theophyllines [7]. Since beta agonists or 
theophyllines have sometimes been used to the extent 
that side effects occur, the addition of ipratropium to the 
treatment program of a given patient may allow for in- 
creased bionchodilation while permitting the individual 
asthmatic patient to reduce the dosage of the beta-adren- 
ergic agonist or theophylline. In addition, patients with cor- 
onary heart disease, who might be at risk of cardiac ar- 
rhythmias from beta agonists or theophyllines, may bene- 
fit from the use of ipratropium because of its lack of car- 
diac side effects. Similarly, patients receiving multiple 
drugs for hypertension and cardiac problems, including 
arrhythmias, might be better served with ipratropium, 
since many of the beta-adrenergic agonists and theophyll- 
ine compounds may have effects on blood pressure as 
well as on cardiac rhythm. 
Thus, although bronchodilation with ipratropium is not 
as rapid in onset as that with the beta-adrenergic ago- 
nists, it has a very wide margin of safety and a tendency 
for a longer duration of bronchodilation. Therefore, it 
should be very useful as an adjunct in our current thera- 
peutic program for asthma. 
SUMMARY 
This go-day, double-blivd, parallel, randomized study 
compared the efficacy and safety of a metered-dose in- 
haler containing ipratropium bromide with those of a simi- 
lar -inhaler containing metaproterenol sulfate in 164 pa- 
tients with asthma. Both drugs showed equal bronchodila- 
tor efficacy on all pulmonary function study days, as 
measured by the area under the FEV, curve. In patients 
who showed a response to the drugs, the onset of a 15 
percent increase in FEV, was slower and the duration 
more prolonged with ipratropium than with metaprotere- 
nol, although these differences were not statistically sig- 
nificant. 
The symptGmatic improvement in asthma reported by 
both the ipratropium and the metaproterenol groups was 
equivalent. The only significant side effects noted with the 
use of ipratropium during the go-day study were cough 
and exacerbation of symptoms; no anticholinergic side 
effects were noted. 
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Discussion 
Dr. Edward Bergofsky: This study indicates a decreas- 
ing response to metaproterenol over the go-day period. I 
wonder whether this response demonstrates tachyphy- 
taxis or just a worsening of asthma in the metaproterenol 
group. Could you comment on that? 
Dr. William Storms: The attenuation of response to 
metaproterenol suggests that tachyphylaxis is not ob- 
served with ipratropium. The study was not designed spe- 
cifically to evaluate tachyphylaxis or tolerance, and I 
therefore cannot make any conclusions on this point. The 
results do tend to suggest, however, a lack of tachyphy- 
laxis with ipratropium. 
Dr. Roberta Goldring: It has been suggested that the 
study design would tend to bias the results in favor of a 
beta agonist rather than an anticholinergic, because one 
of the entry criteria was a significant response to a beta 
agonist. Despite this criterion, a large number of patients 
did not show a response to metaproterenol during the 
course of the go-day trial. Can you explain this? 
Dr. Storms: Patients had to show a response to isopro- 
terenol before entering the study. Once the study began, 
30 percent of patients in the metaproterenol group did not 
show a response to the first dose, and when that sub- 
group was examined more closely, we discovered that a 
number of these non-responding patients had a FEV, 
value greater than 75 percent of predicted; they actually 
had too good a level of bronchodilation on the first study 
day for their FEV, value to improve by 15 percent. When 
these patients were excluded, more than 90 percent of the 
metaproterenol group did show a response. So some of 
our finding of non-responsiveness to metaproterenol was 
due to a difference in the patients’ baseline pulmonary 
function on day 1 as compared with their previous qualifi- 
cation test. 
Dr. Nicholas Gross: This brings up something I am con- 
cerned about. Classifying asthma patients as responders 
or non-responders is quite bothersome to me, because, 
as was just shown, baseline values have a lot to do with 
how much of a response will be observed. If the baseline 
is high, and a 15 percent FEV, response is required, that 
response may be too great for these patients to achieve. I 
would therefore suggest that we calculate the response in 
terms of the achievable response. That would eliminate 
arbitrariness. For instance, if a patient has a baseline 
FEV, of 75 percent of predicted, response could be calcu- 
lated by comparing that 75 percent to the highest values 
obtained in the patient. 
Dr. John O’Hollareh: I would like to add a point about 
study follow-up. One thing we should emphasize in this 
study was the need for concomitant medication in those 
patients who showed a response to ipratropium. It is my 
impression, however, that responders have reduced 
needs for concomitant therapy compared with non- 
responders. Three patients in this study who had been 
steroid-dependent are now taking only ipratropium four 
times a day, and there are no signs of tachyphylaxis. 
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